Filgotinib Shaping Up To Be Success Story For Gilead and Galapagos

Impressive Phase II data for Gilead and Galapagos’ filgotinib in psoriatic arthritis and progress into Phase III for ulcerative colitis suggest that the investigational JAK inhibitor could potentially become a market leader in the class for these and other inflammatory indications.

SC1805_Growth Concept_1029299632_1200.jpg
Filgotinib climbing up the clinical ladder • Source: Shutterstock

Gilead Sciences Inc.'s and Galapagos NV's view that filgotinib has considerable potential as a treatment for range of inflammatory diseases has been supported by more clinical progress for the oral Janus kinase (JAK) inhibitor, this time in psoriatic arthritis (PsA) and ulcerative colitis (UC).

First up, the firms unveiled data from the Phase II EQUATOR study which showed filgotinib achieved its primary endpoint of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

More from Therapy Areas